Generic User Fees Get Another Hearing As FDA Seeks More Public Comment
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency may not feel all industry sector voices have been heard and wants to provide another opportunity for input at the May 10 session, but negotiations with GPhA and API groups are continuing.
You may also be interested in...
Generic User Fees Would Create 10-Month ANDA Review Time
Annual revenue of $250 million to $300 million in generic drug user fees is discussed as FDA unveils its "four walls and a roof" guiding principles.
Generic User Fees Would Create 10-Month ANDA Review Time
Annual revenue of $250 million to $300 million in generic drug user fees is discussed as FDA unveils its "four walls and a roof" guiding principles.
GDUFA Talks: FDA Reminds Industry The Program Is Generic-Only
Generic drug user fee negotiations began with a reminder that components of the program will not apply to other regulated drug sectors.